article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

470% price increases

World of DTC Marketing

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. AbbVie’s yearly U.S. billion in 2020. billion in 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Web of Science Grants Index helps researchers develop more targeted grant proposals

Clarivate

Competition for funding is tough and researchers need help to make their grant applications stand out. While some funding programs have seen spending increase year over year, the competition remains tough: researchers often face just a 10 – 20% chance of winning a grant award. in 2022 was 20.7%.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

” Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS average at around 7%, before skyrocketing to 19% in 2022 ahead of a government agreed cap at 15%. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.”

Pharma 72
article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 59
article thumbnail

Cutting the combination therapy access issue down to size

pharmaphorum

This access conundrum was acknowledged by NICE as far back as 2014, and has been sitting in pharma’s “inbox” for some time. The ABPI, for example, is working with the Competition Markets Authority to develop guidance on compliant pricing conversations. Too hard to fix? At the same time, interest from NICE and NHS England is growing.